Survival values according to conventional responses and for different levels of minimal residual disease determined by deep sequencing, multiparametric flow cytometry, or ASO-PCR
| . | . | Time to progression . | Overall survival . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| All series . | N . | 5 y, % . | Median mo (±95% CI) . | HR . | P value . | 5 y, % . | Median mo (±95% CI) . | HR . | P value . |
| SEQ <10−5 | 30 | 84 | 80 (48-112) | 5.39 | .0001 | 89 | NR | 4.88 | .019 |
| SEQ >10−5 | 80 | 29 | 31 (26-37) | 65 | 81 (40-122) | ||||
| MFC <10−5 | 34 | 66 | NR | 3.97 | .0001 | 82 | NR | 2.17 | .046 |
| MFC >10−5 | 65 | 32 | 32 (24-40) | 66 | 110 (50-170) | ||||
| ASO-PCR 10−5 | 22 | 65 | NR | 4.59 | .03 | 81 | NR | — | .340 |
| ASO-PCR >10−5 | 19 | 0 | 26 (20-32) | 81 | NR | ||||
| Conventional response and MRD | |||||||||
| VGPR | 48 | 31 | 29 (18-40) | 2.00 | .001 | 61 | 110 (35-184) | 2.17 | .022 |
| CR | 62 | 49 | 60 (39-80) | 78 | NR | ||||
| CR & SEQ <10−5 | 26 | 82 | 131 (51-154) | 2.87 | .001 | 88 | NR | — | .172 |
| CR & SEQ >10−5 | 36 | 31 | 35 (30-41) | 71 | NR | ||||
| CR & MFC <10−5 | 28 | 65 | NR | 2.87 | .06 | 78 | NR | — | .596 |
| CR & MFC >10−5 | 33 | 37 | 35 (30-41) | 77 | NR | ||||
| . | . | Time to progression . | Overall survival . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| All series . | N . | 5 y, % . | Median mo (±95% CI) . | HR . | P value . | 5 y, % . | Median mo (±95% CI) . | HR . | P value . |
| SEQ <10−5 | 30 | 84 | 80 (48-112) | 5.39 | .0001 | 89 | NR | 4.88 | .019 |
| SEQ >10−5 | 80 | 29 | 31 (26-37) | 65 | 81 (40-122) | ||||
| MFC <10−5 | 34 | 66 | NR | 3.97 | .0001 | 82 | NR | 2.17 | .046 |
| MFC >10−5 | 65 | 32 | 32 (24-40) | 66 | 110 (50-170) | ||||
| ASO-PCR 10−5 | 22 | 65 | NR | 4.59 | .03 | 81 | NR | — | .340 |
| ASO-PCR >10−5 | 19 | 0 | 26 (20-32) | 81 | NR | ||||
| Conventional response and MRD | |||||||||
| VGPR | 48 | 31 | 29 (18-40) | 2.00 | .001 | 61 | 110 (35-184) | 2.17 | .022 |
| CR | 62 | 49 | 60 (39-80) | 78 | NR | ||||
| CR & SEQ <10−5 | 26 | 82 | 131 (51-154) | 2.87 | .001 | 88 | NR | — | .172 |
| CR & SEQ >10−5 | 36 | 31 | 35 (30-41) | 71 | NR | ||||
| CR & MFC <10−5 | 28 | 65 | NR | 2.87 | .06 | 78 | NR | — | .596 |
| CR & MFC >10−5 | 33 | 37 | 35 (30-41) | 77 | NR | ||||
SEQ, minimal residual disease by deep sequencing.